

Hepatitis C Virus: Fresh Take Gone Stale?

Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.A.Chastain@VUMC.org

Disclosures


- Dr. Chastain receives grant/research support from Gilead Sciences, Inc.:
 - Site investigator for HIV/HCV SWITCH Registry Study
 - Key faculty personnel for Gilead FOCUS HCV Screening Program through Vanderbilt University Medical Center Emergency Department





At the end of this lecture, the learner will be able to:

- Review trends in epidemiology of hepatitis C virus (HCV)
- Understand the indications for screening for HCV
- Identify the clinical manifestations of HCV
- Discuss the principles of and indications for treatment of HCV






Objectives

At the end of this learner will be a

- Review trend epidemiology virus (HCV)
- Understand for screening
- Identify the c manifestations
- Discuss the princ and indications for of HCV






My "Real" Objectives

At the end of this lecture, the learner will:

- Recognize that HCV remains a major public health and individual health concern.
- Identify interventions related to HCV within his/her practice and/or community.
- Commit to a personal change re: the HCV continuum of care.





Outline

Yesterday's News (i.e. Why We Were Excited)

The Stale Take (i.e. The Party Line)

A Call To Action (i.e. The Opportunities Abound)

That Which Still Remains (i.e. Work To Do)



Outline

Yesterday's News (i.e. Why We Were Excited)

The Stale Take (i.e. The Party Line)

A Call To Action (i.e. The Opportunities Abound)

That Which Still Remains (i.e. Work To Do)



Audience Response #1: Word Cloud

What words do you associate with hepatitis C?



Audience Response #2: Word Cloud

What words do you associate with hepatitis C treatment?




Hepatitis

- Hepatitis = inflammation of the liver
- Differential Diagnosis:
 - Hepatitis viruses
 - Hepatitis A (HAV)
 - Hepatitis B (HBV)
 - Hepatitis C (HCV)
 - HIV
 - Cytomegalovirus (CMV)
 - Alcohol
 - Drug and/or supplement toxicity
 - Obesity [leading to non-alcoholic fatty liver disease (NAFLD)]
 - Genetic disorders




Hepatitis C Virus (HCV)

- Single-strand, positive sense RNA flavivirus
- Spread through blood and body fluids
- Predominantly infects liver cells
- No latent reservoir
 - I.e. no integration with host DNA as with HIV
 - I.e. no covalently closed DNA within host cells
 - I.e. can be eradicated/cured







HCV Epidemiology & Natural History

Epidemiology


- 2.3-6 million Americans infected with HCV
- Peak rates of decompensated cirrhosis and hepatocellular carcinoma 2020 in some estimates.
- Peak mortality peak in 2034 per other estimates.

Natural history

- Minority develop advanced liver disease
- Cirrhosis usually takes years to develop in the absence of comorbidities
- Timeline may be accelerated by comorbidities, including alcohol use, HBV, HIV, insulin resistance, and/or obesity

Davis GL et al. *Gastroenterology* 2010. // Ditah I et al *J Hepatol* 2014. // Edlin BR et al *Hepatology* 2015. // Rein DB et al *Dig* & *Liver Disease* 2011. // www.cdc.gov/hepatitis/HCV


Estimated HCV Ab Prevalence Rate / 100,000 persons



HepVu (www.hepvu.org). Emory University, Rollins School of Public Health.



Rate of Deaths Related to HCV per 100,000 persons



HepVu (www.hepvu.org). Emory University, Rollins School of Public Health.




Audience Response

 Which disease(s) kill more Americans each year? A. HCV

B. All other reportable infections that the CDC tracks (including HIV, TB, and hepatitis B)



HCV and Mortality in the USA




Source: Centers for Disease Control and Prevention



Ly KN et al. Clin Infect Dis 2016.

Effective Treatment Will Significantly Reduce Mortality from HCV Infection¹⁴





AETC AIDS Education & Training Center Pl

Southeast

van der Meer AJ et al. JAMA. 2012

Treatment Response in Direct Acting Antiviral (DAA) Era 100 80 SVR (%) 60 40 20 0 IFN PEGIFIN IFN* PEN IFN PEGIFINER DAA* PEGIFINER D



Slide courtesy of and adapted from Dr. Susanna Naggie

HCV Approved Agents

FDA Approved Therapies Through 2010

Interferon (1986) Ribavirin (1998) Pegylated Interferon (2001)

Since Then

Telaprevir (2011) Boceprevir (2011) Simeprevir (2013) Sofosbuvir (2013) Ledipasvir (2014) Paritaprevir (2014) Ombitasvir (2014) Dasabuvir (2014) Daclatasvir (2015) Elbasvir (2016) Grazoprevir (2016) Velpatasvir (2016) Voxilaprevir (2017) Glecaprevir (2017) Pibrentasvir (2017)



HCV Therapies: The Past, Present, and Future

Velpatasvir

<u>Pre-2011</u>	<u>July 2011</u>	Nov-Dec 2013	<u>Oct-Dec 2014</u>	<u>July 2015</u>	<u>Jan-Jun 2016</u>	<u>July-Aug 2017</u>
IFN PEG-IFN RBV	IFN PEG-IFN RBV Telaprevir Boceprevir	IFN PEG-IFN RBV Telaprevir Boceprevir Simeprevir Sofosbuvi	IFN PEG-IFN RBV Telaprevir Boceprevir Simeprevir Sofosbuvir Ledipasvir Paritaprevir Ombitasvir Dasabuvir	IFN PEG-IFN RBV Telaprevir Boceprevir Sofosbuvir Sofosbuvir Ledipasvir Paritaprevir Ombitasvir Dasabuvir	IFN PEG-IFN RBV Telaprevir Boceprevir Simeprevir Sofosbuvir Sofosbuvir Ledipasvir Paritaprevir Ombitasvir Dasabuvir Daclatasvir Elbasvir Grazoprevir	IFN PEG-IFN RBV Telaprevir Boceprevir Simeprevir Sofosbuvir Ledipasvir Paritaprevir Ombitasvir Dasabuvir Dasabuvir Daclatasvir Elbasvir Grazoprevir Velpatasvir Voxilaprevir Glecaprevir Pibrentasvir



FDA Approved HCV Therapies

Nonspecific Antivirals

Interferon (IFN) Ribavirin (RBV) Pegylated Interferon (PEG-IFN)

NS3/4 Protease Inhibitors

Telaprevir (TPV) Boceprevir (BPV) Simeprevir (SMV) Paritaprevir (PTV) Grazoprevir (GZP) Voxilaprevir (VOX) Glecaprevir (GLE)

NS5A Inhibitors

Ledipasvir (LDV) Ombitasvir (OBV) Daclatasvir (DCV) Elbasvir (EBV) Velpatasvir (VEL) Pibrentasvir (PIB)

NS5B Polymerase Inhibitors

Sofosbuvir (SOF) Dasabuvir (DBV)



Goals for HCV Therapy

- Interferon-free
- Ribavirin-free
- Improved efficacy overall
- Improved efficacy for subgroups (i.e. black, HIV/HCV)
- Decreased side effects
- Minimal drug-drug interactions
- Increased genotype options (including pangenotypic)
- Options in renal impairment
- Retreatment options
- Lower prices
- Accessibility for all



Goals for HCV Therapy

- Interferon-free
- Ribavirin-free
- Improved efficacy overall
- Improved efficacy for subgroups (i.e. black, HIV/HCV)
- Decreased side effects
- Minimal drug-drug interactions
- Increased genotype options (including pangenotypic)
- Options in renal impairment
- Retreatment options
- Lower prices
- Accessibility for all



Outline

Yesterday's News (i.e. Why We Were Excited)

- The Stale Take (i.e. The Party Line)
- A Call To Action (i.e. The Opportunities Abound)


That Which Still Remains (i.e. Work To Do)



What Hasn't Changed?

- Rate of New Infections
- Treatment Options
- Treatment Capacity








Reported Cases of <u>Acute</u> HCV in Tennessee


		<u>2011</u>	<u>2012</u>	<u>2013</u>	<u>2014</u>	<u>2015</u>	<u>2016</u>
US	case rate	0.4	0.6	0.7	0.7	0.8	1.0
	cases	1,229	1,778	2,138	2,194	2,436	2,967
TN	case rate	1.3	2.0	1.5	1.9	2.6	2.3
	cases						
	rank	4 th	4 th	6 th	5 th	4 th	5 th





http://www.cdc.gov/hepatitis/statistics/2015surveillance/pdfs/2015hepsurveillancerpt.pdf * per 100,000 population

Distribution of Acute HCV Case Rates in TN (2016)






Tennessee NBS, accessed February 10, 2017 Tennessee eHARS, accessed June 30, 2017 opulation Source, American Community Survey 2011-2015 County Averages

Pregnant Women and HCV Cont.

Rate of HCV Among Pregnant Women Per 1000 Live Births in US and TN






Patrick SW et al. MMWR 2017.

Pregnant Women and HCV Cont.

Rate of HCV Among Pregnant Women Per 1000 Live Births in US and TN



HCV Therapies: The Past, Present, and Future

<u>Pre-2011</u>	<u>July 2011</u>	Nov-Dec 2013	Oct-Dec 2014	<u>July 2015</u>	<u>Jan-Jun 2016</u>	<u>July-Aug 2017</u>	<u>?????</u>
IFN PEG-IFN RBV	IFN PEG-IFN RBV Telaprevir Boceprevir	IFN PEG-IFN RBV Telaprevir Boceprevir Simeprevir Sofosbuvir	IFN PEG-IFN RBV Telaprevir Boceprevir Simeprevir Sofosbuvir Ledipasvir Paritaprevir Ombitasvir Dasabuvir	IFN PEG-IFN RBV Telaprevir Boceprevir Sofosbuvir Sofosbuvir Ledipasvir Paritaprevir Dasabuvir Dasabuvir	IFN PEG-IFN RBV Telaprevir Boceprevir Simeprevir Sofosbuvir Sofosbuvir Ledipasvir Paritaprevir Ombitasvir Dasabuvir Dasabuvir Basabuvir Basabuvir Basabuvir Basabuvir Basabuvir Basabuvir Basabuvir Basabuvir Basabuvir Basabuvir Basabuvir Basabuvir Basabuvir	IFN PEG-IFN RBV Telaprevir Boceprevir Simeprevir Sofosbuvir Ledipasvir Paritaprevir Ombitasvir Dasabuvir Daclatasvir Elbasvir Grazoprevir Velpatasvir Voxilaprevir Glecaprevir Pibrentasvir	



Treatment Capacity

- Providers with HCV training can deliver excellent cure rates in community practice
 - Nonrandomized open-label clinical trial
 - Included NPs, PCPs, and Specialists
 - 600 patients
 - SVR 89.3% vs. 86.9% vs. 83.8% (with specialists LOWEST)
- Uptake among non-specialist providers remains low to date

	SVR	Patients With SVR/	
Provider	Rate	Total Patients, n/N	SVR Rate (95%CI)
NPs		1	
NP 1	0.77	33/43	
NP 2	1.00	12/12	
NP 3	0.80	4/5	
NP 4	1.00	30/30	—
NP 5	0.92	55/60	+
PCPs			
PCP 1	0.75	24/32	
PCP 2	1.00	19/19	—
PCP 3	0.88	43/49	+
PCP 4	0.88	21/24	
PCP 5	0.89	32/36	
Specialists			
Specialist 1	0.77	47/61	
Specialist 2	0.85	50/59	+
Specialist 3	0.89	34/38	
Specialist 4	0.76	13/17	
Specialist 5	0.94	35/37	+
Specialist 6	0.82	64/78	+
		Ļ	0.5 1.0



Outline

Yesterday's News (i.e. Why We Were Excited)

The Stale Take (i.e. The Party Line)

A Call To Action (i.e. The Opportunities Abound)

That Which Still Remains (i.e. Work To Do)



Manifestations of HCV

- Acute HCV
 - Fever
 - Fatigue and anorexia
 - Nausea and vomiting
 - Abdominal pain
 - Jaundice, dark urine, and claycolored stools
 - Arthralgias

- Chronic HCV
 - Often asymptomatic
 - Associated with fatigue, insomnia, depression, and mental status changes
 - Associated with extrahepatic manifestations including vasculitis and renal disease
 - Long-term outcomes include cirrhosis, liver failure, and hepatocellular carcinoma



Immune-related extrahepatic manifestations

- Mixed cryoglobulinemia
- Cryoglobulinemic vasculitis
- B-cell NHL
- Sicca syndrome
- Arthralgia/myalgia
- Autoantibody production (i.e. cryoglobulins, rheumatoid factor, and antinuclear, anticardiolipin, antithyroid and anti-smooth muscle antibodies)
- Polyarteritis nodosa
- Monoclonal gammopathies
- Immune thrombocytopenia

Inflammatory-related extrahepatic manifestations

- Type 2 diabetes mellitus type 2
- Insulin resistance
- Glomerulonephritis
- Renal insufficiency
- Fatigue
- Cognitive impairment
- Depression
- Impaired quality of life
- Polyarthritis/fibromyalgia
- Cardiovascular disorders (i.e. stroke, ischemic heart disease)



How Does HCV Treatment Impact Major Extrahepatic Outcomes?

- Cumulative 8-year outcomes for patients with SVR resulted in decreased risk of :
 - Acute coronary syndrome (HR 0.77)
 - Ischemic stroke (HR 0.62)
 - ESRD (HR 0.15)
- Cumulative ~5-year outcomes for cirrhotic patients with SVR resulted in decreased risk of:
 - Major adverse cardiovascular event (HR 0.35)



Hsu Y-C et al. *Gut* 2015. // Cacoub P et al. *Am Heart Journal* 2018.

HCV, Extrahepatic Disease, and Quality of Life

- HCV SVR results in the following:
 - Remission in cryoglobulinemia
 - Treatment response in B cell lymphoma
 - Improved insulin resistance
 - Reduced incidence of diabetes
 - Improved health-related quality of life and related work productivity



Cacoub P et al. Gut 2018. // Younossi ZM et al. AASLD The Liver Meeting 2017 Abstract 64.

HCV Cure and Health

- Lower liver-related and all-cause mortality
- Improved outcomes of non-hepatic conditions
- Increased quality of life and work productivity

 Treatment is recommended for ALL patients with chronic HCV (except those with short life expectancies due to unrelated causes)




Outline

Yesterday's News (i.e. Why We Were Excited)

The Stale Take (i.e. The Party Line)

- A Call To Action (i.e. The Opportunities Abound)
- That Which Still Remains (i.e. Work To Do)






AETC AIDS Education & Training Center Program Southeast

Yehia BR et al. PLoS One 2014.

Who is at Risk for HCV?

- IV drug users
- Tattoo/piercing recipients
- Blood/clotting protein recipients prior to 1992
- Mother-to-child transmission from HCV+ mother
- Hemodialysis patients
- People with HIV
- Occupational exposures
- Born between 1945-1965 ("baby boomers")





Diagnostics Review

- HCV Antibody
 - Tests for exposure
 - Near 100% sensitivity once >6 months after infection
- HCV RNA
 - Tests for active infection
 - ~20% of patients spontaneously clear HCV
- HCV Genotype
 - Defines genetic subtype for prognostic information and treatment guidance





- Remember those at risk
- Implement screening program within your work setting
- Educate other colleagues re: risk and need for screening



Linkage to Care

- Identify treating physicians in your area
- Consider developing treatment capacity within your practice
- Contact for options/questions:
 - Cody Chastain @ cody.a.chastain@VUMC.org
 - Kimberly Gill, TN Department of Health @ kimberly.gill@tn.gov




INVITED ARTICLE VIRAL HEPATITIS

Camilla S. Graham, Section Editor

Evaluation

- Assist in medical evaluation
- Utilize available resources for education and clinical care
- Ensure access to provider that prescribes HCV treatment



Norbert Bräu^{1,2}


¹Divisions of Liver Diseases and Infectious Diseases, Mount Sinai School of Medicine, New York, and ²Bronx VA Medical Center, Bronx, New York

 Clinical Infectious Diseases
 2013;56(6):853–60

 Published by Oxford University Press on behalf of the Infectious Diseases Society of

 America 2012.

 DOI: 10.1093/cid/cis957






Treatment

- Three medications now are used for the vast majority of infections
 - Glecaprevir/pibrentasvir can be used in ALL genotypes for 8 weeks (in patients without cirrhosis and without prior treatment) or 12 weeks
 - Sofosbuvir/velpatasvir can be used in ALL genotypes for 12 weeks
- Few adverse effects
- Minimal monitoring requirements
- Prescriber restrictions decreasing nationally



"The Committee's Conclusions Regarding Targets for Hepatitis C Elimination"

- "A 90 percent reduction in incidence of hepatitis C (relative to the 2015 incidence carried forward) is possible in the United States by 2030. Meeting this goal will require treatment without restrictions on severity of disease and a consistent ability to diagnose new cases, even as prevalence decreases."
- "The same levels of diagnosis and treatment would reduce mortality from hepatitis C in 2030 to 65 percent relative to 2015, and avert 28,800 deaths by 2030."
- "Meeting these targets depends on diagnosing at least 110,000 cases a year until 2020, almost 89,000 a year between 2020 and 2024, and over 70,000 each year between 2025 and 2030."





The Path to Elimination: An ID Physician's View

- Enhanced public health surveillance
- Expansion of access to prevention services
- Expansion of screening
- Removal of barriers to treatment
- National coordination of surveillance, research, and capacity

Kim A. Clin Infect Dis 2017.



Make A Change!

- New diagnostic testing makes it easier to assess HCV than ever before.
- New therapies have streamlined approach to HCV treatment.
- Multiple training resources available for provider education for those interested in treating HCV directly.
- Email me!
 - Cody.A.Chastain@VUMC.org



Summary

- HCV is a major cause of morbidity and mortality in our country, region, and state.
- Treatment of HCV can improve many patient outcomes.
- New treatments are well tolerated and dramatically effective.
- Screening, diagnosis, and treatment are critical to impacting the HCV epidemic.
- You can make an impact!



Thank You!

Questions?

Cody.A.Chastain@VUMC.org

